PSA screening for prostate cancer: Why saying no is a high-value health care choice

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 12, 2015, Pages 1566-1574

  Wilt, Timothy J ^a,b   Dahm, Philipp ^b,c  

^a VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c Minneapolis Veterans Affairs Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER SCREENING; CONCEPTUAL FRAMEWORK; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; MALE; PRACTICE GUIDELINE; PROSTATE CANCER; REVIEW; BLOOD; COST BENEFIT ANALYSIS; DECISION MAKING; EARLY CANCER DIAGNOSIS; HEALTH CARE DELIVERY; HEALTH SERVICE; MORTALITY; PROCEDURES; PROSTATIC NEOPLASMS; STANDARDS;

COST-BENEFIT ANALYSIS; DECISION MAKING; DELIVERY OF HEALTH CARE; EARLY DETECTION OF CANCER; HUMANS; MALE; MEDICAL OVERUSE; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84951026391     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0182     Document Type: Review

References (36)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. Harris RP, Wilt TJ, Qaseem A; on behalf of the High Value Care Task Force of the American College of Physicians. A value framework for cancer screening: advice for high value care from the American College of Physicians. Ann Intern Med 2015;162:712-717.
3. Wilt TJ, Harris RP, Qaseem A; on behalf of the High Value Care Task Force of the American College of Physicians. Screening for cancer: advice for high value care from the American College of Physicians. Ann Intern Med 2015;162:718-725.
4. Wilt TJ, Partin MR. Screening: simple messages...sometimes. Arch Intern Med 2011;171:2046-2048.
5. Moyer VA. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120-123.
6. Wilt TJ Scardino PT, Carlsson SV, Basch E. Prostate-specific antigen screening in prostate cancer: perspectives on the evidence. J Natl Cancer Inst 2014;106:1-6.
7. Owens DK, Qaseem A, Chou R, Shekelle P; for the Clinical Guidelines Committee of the American College of Physicians. Cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. Ann Intern Med 2011;154:174-180.
8. Welch HG, Schwartz LM, Woloshin S. Overdiagnosed. Making People Sick in the Pursuit of Health. Boston: Beacon Press; 2011.
9. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014:384:2027-2035.
10. Ilic D, Dahm P. Prostate cancer screening in Europe. Lancet 2015;385:1506.
11. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev 2013;1:CD004720.
12. Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002;94:167-173.
13. Dubben HH. Trials of prostate-cancer screening are not worthwhile. Lancet Oncol 2009;10:294-298.
14. Basch E, Oliver TK, Vickers A, et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion. J Clin Oncol 2012;30:3020-3025.
15. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. Available at: http://www.auanet.org/education/guidelines/prostate-cancer-detection. cfm. Accessed August 5, 2015.
16. Donovan J, Mills N, Smith M, et al. Quality improvement report: improving design and conduct of randomized trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. BMJ 2002;325:766-770.
17. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for early prostate cancer. N Engl J Med 2012;367:203-213.
18. Bill-Axelson A, Holmberg I, Garmo H, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer. N Engl J Med 2014;370:932-940.
19. Widmark A, Tomic R, Modig J, et al. Prospective randomized trial comparing external beam radiotherapy versus watchful waiting in early prostate cancer (T1b-T2, pN0, grade 1-2, M0). Presented at the 53rd Annual ASTRO Meeting; October 26, 2011; Miami Beach, Florida.
20. Ma X, Wang R, Long JB, et al. The cost implications of prostate cancer screening in the medicare population. Cancer 2014;120:96-102.
21. Shteynshlyuger A, Andriole GL. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer. J Urol 2011;185:828-832.
22. Pataky R, Gulati R, Etzioni R, et al. Is prostate cancer screening costeffective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. Int J Cancer 2014;135:939-947.
23. Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012;367:595-605.
24. Sammon JD, Pucheril D, Diaz M, et al. Contemporary nationwide patterns of self-reported prostate-specific antigen screening. JAMA Intern Med 2014;174:1839-1841.
25. Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer. JAMA 2015;314:80-81.
26. Maurice MJ, Abouassaly R, Kim SP, Zhu H. Contemporary nationwide patterns of active surveillance use for prostate cancer. JAMA Intern Med 2015;175:1569-1571.
27. Hayes JH, Ollendorf DA, Pearson, SD, et al. Observation versus initial treatment for men with localized, low-risk prostate cancer: a costeffectiveness analysis. Ann Intern Med 2013;158:853-860.
28. Prasad V. It's time to stop screening for prostate cancer. JAMA Intern Med 2014;174:1841-1842.
29. Carroll PR, Parsons JK, Andriole G, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Version 2.2015. Available at: NCCN.org. Accessed July 30, 2015.
30. Howard K, Barratt A, Mann GJ, et al. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices. Arch Intern Med 2009;169:1603.
31. Welch HG. Making the call. JAMA 2011;306:2649-2650.
32. Partin MR, Nelson D, Radosevich D. Randomized trial examining the effect of two prostate cancer screening educational interventions on patient knowledge, preferences and behaviors. J Gen Intern Med 2004;19:835-842.
33. Lillie SE, Partin MR, Rice K, et al. The effects of shared decision making on cancer screening-a systematic review. Washington, DC: Department of Veterans Affairs (US); 2014.
34. Carlsson S, Assel M, Sjoberg D, et al. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ 2014;348:g2296.
35. Wilt TJ, Dahm P. PSA screening for prostate cancer. BMJ 2014;348:g2559.
36. Ganz PA, Barry JM, Burke W, et al. National Institutes of Health state-of the-science conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med 2012;156:591-595.